JOHNS HOPKINS UNIVERSITY

A BMJ investigation has revealed evidence of serious misreporting in two clinical trials that were pivotal to ticagrelor's approval by the FDA and UK regulators.

Infinity Bio closed an $8 million Series A financing round led by Illumina Ventures to expand its proprietary MIPSA™ antibody reactome profiling platform.

A peer-reviewed narrative review published in Cureus journal highlights the therapeutic potential of long-acting synthetic cannabidiol (CBD) for chronic pain management as a non-opioid alternative.

The CheckMate 816 phase 3 trial demonstrates that patients with resectable non-small cell lung cancer who received nivolumab plus chemotherapy before surgery had approximately 10% higher survival rates at 5 years compared to chemotherapy alone.

LP-184 showed remarkable survival improvements in mouse models of atypical teratoid rhabdoid tumors (ATRT), with median survival increasing by 345% in one model (p<0.0001).

The Maryland Stem Cell Research Commission has awarded over $18 million in grants to 52 investigators working on nearly 50 different medical conditions including sickle cell anemia, diabetes, and various neurological disorders.

Responsive parenting techniques implemented during infancy and toddlerhood led to significantly lower BMI in children through middle childhood, with particularly strong benefits observed in girls.

GLP-1 receptor agonist use has increased dramatically among type 1 diabetes patients, with prescriptions rising from 4% to 33% in severely obese adults over the past decade.

A Johns Hopkins study of 230 patients demonstrates fractionated reirradiation is safe and effective for recurrent high-grade glioma, with median overall survival reaching 10.2 months from treatment initiation.

New research from Johns Hopkins University reveals that semaglutide (Ozempic, Wegovy) is associated with a 32% increased relative risk of nonarteritic anterior ischemic optic neuropathy, a potentially blinding eye condition.